Press release

11 Sep 2020 London, GB

EY appoints a Head of Healthcare Services M&A in the firm’s corporate finance team

EY has made a senior appointment to its life sciences and healthcare corporate finance team in the UK, with the addition of Sylvester Oppong as Head of Healthcare Services M&A.

Press contact

EY UK

Multidisciplinary professional services organisation

EY has made a senior appointment to its life sciences and healthcare corporate finance team in the UK, with the addition of Sylvester Oppong as Head of Healthcare Services M&A.

Sylvester joins EY from Smith Square Partners where he was Head of Healthcare M&A and a Corporate Finance Partner. He brings more than 16 years of corporate finance experience with a dedicated focus on the healthcare services sector during the past ten years.

In his new role Sylvester will be responsible for originating and executing transactions across the UK healthcare sector at EY and will leverage the firm’s global reach to introduce international opportunities to clients.

Sylvester works within EY’s Corporate Finance team led by Fraser Greenshields and alongside David Scourfield in the life sciences and healthcare corporate finance team. David and Sylvester’s team advises entrepreneurs, management teams, corporates (including founder-managed businesses) and private equity firms within the life sciences and healthcare sectors.

Fraser Greenshields, Head of Corporate Finance at EY said: “Sylvester brings additional strength and depth to our experienced corporate finance team. His appointment demonstrates our capabilities and commitment to the healthcare services sector. We are delighted to have him join our ranks especially at a time when we are beginning to see green shoots return to the deals market with an increase in activity.”

Sylvester Oppong commented: “I am delighted to be joining EY where I will build our healthcare services M&A business and develop our team.  The healthcare services sector performed robustly through lockdown with specialist care and digital healthcare proving to be particularly resilient to market challenges. M&A activity within this sector is expected to rebound strongly from the pause caused by lockdown with a swell of deals expected in the remainder of the year through to 2021.”